Biological Response Modifiers in the Treatment of Malignant Brain Tumours: Role of Interferons and Retinoids

Authors: Uhm J.H.1; Yung W.K.A.1

Source: CNS Drugs, Volume 10, Number 1, July 1998 , pp. 11-24(14)

Publisher: Adis International

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content

Abstract:

The retinoids and type I interferons constitute the 2 principal classes of biological response modifiers (BRMs) that have demonstrated activity in the treatment of malignant cerebral tumours, and are associated with fewer of the adverse effects induced by conventional chemotherapeutic agents. These BRMs share numerous common characteristics that may underlie their observed clinical efficacy. First, both classes of agent activate intracellular signal transduction pathways that, at numerous points, are capable of antagonising the oncogenic effects of growth factor-stimulated pathways in tumour cells. Secondly, the intracellular signals initiated by these BRMs ultimately lead to the activation of a multitude of genes; these genes, in turn, encode anti-tumourigenic functions that are distinct from the classic cytotoxic effects of conventional chemotherapeutic agents, such as the induction of differentiation and the inhibition of angiogenesis. Thirdly, while both classes of BRMs have demonstrated encouraging results in clinical trials when used as monotherapy, there is evidence that they may act synergistically when used in combination with each other or with conventional chemotherapeutic agents. With further refinements, the BRMs may develop into important adjunctive agents in the treatment of patients with malignant brain tumours.

Keywords: Reviews-on-treatment; Brain-cancer, treatment; Retinoids, pharmacodynamics; Retinoids, therapeutic-use; Retinoids, drug-interactions; Drug-interactions; Interferon, therapeutic-use; Interferon, pharmacodynamics; Interferon, pharmacokinetics; Drug-resistance; Antineoplastics, therapeutic-use

Language: English

Document Type: Leading article

Affiliations: 1: Department of Neuro-Oncology, The University of Texas, MD Anderson Cancer Center, Houston, Texas, USA *

The full text electronic article is available for purchase. You will be able to download the full text electronic article after payment.

$57.95 plus tax      Refund Policy

 

OR

Back to top

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content
Share this item with others: These icons link to social bookmarking sites where readers can share and discover new web pages.
Page Help Click here for Page Help
Shopping cart
Tools
Sign in






Need to register?
Sign up here
Text size: A | A | A | A